private financing

The deals are with institutional investors and more than 1 million American Depositary Shares will be offered at A$1.75 per ADS.

The firm plans to use the cash to support commercial expansion of its NIPT to all US states and fund R&D for future diagnostic tests, including liquid biopsies.

The Cambridge, UK-based gene synthesis firm plans to use the funds to accelerate development of its silicon platform and introduce a desktop device.

La Jolla, California-based DermTech has agreed to sell common and preferred stock to a number of undisclosed institutional investors.

The financing follows InformedDNA's signing of definitive agreements to receive growth capital investments with a number of investment groups.

The company is developing an RNA sequencing kit based on a technology that enables barcoding in a test tube format to prepare samples for single-cell profiling.

The company is developing a platform that is designed to provide an overview of an individual's health based on sequenced genetic data and other metrics.

The Series B round, which includes new and existing investors, follows the Belgian firm's completion of a €7.7 million private placement in 2016.

The firm, cofounded by several Harvard University researchers, is commercializing a single-cell spatial transcriptomics technology called MERFISH. 

The University of Utah spinout said it will use the funding to enhance and expand its NGS-based Explify microbe identification platform and support its lab.